327 related articles for article (PubMed ID: 25071023)
21. Magnetic resonance assessment of the cerebral alterations associated with obesity development.
Lizarbe B; Campillo B; Guadilla I; López-Larrubia P; Cerdán S
J Cereb Blood Flow Metab; 2020 Nov; 40(11):2135-2151. PubMed ID: 32703110
[TBL] [Abstract][Full Text] [Related]
22. Corrigendum to "More complex than you might think: Neural representations of food reward value in obesity" [Appetite 178 (2022) 106164].
Pimpini L; Kochs S; Frannsen S; van den Hurk J; Valente G; Roebroeck A; Jansen A; Roefs A
Appetite; 2023 Dec; 191():107079. PubMed ID: 37858485
[No Abstract] [Full Text] [Related]
23. Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans.
van Bloemendaal L; Veltman DJ; Ten Kulve JS; Groot PF; Ruhé HG; Barkhof F; Sloan JH; Diamant M; Ijzerman RG
Diabetes Obes Metab; 2015 Sep; 17(9):878-86. PubMed ID: 26094857
[TBL] [Abstract][Full Text] [Related]
24. Emotional eating is associated with increased brain responses to food-cues and reduced sensitivity to GLP-1 receptor activation.
van Bloemendaal L; Veltman DJ; ten Kulve JS; Drent ML; Barkhof F; Diamant M; IJzerman RG
Obesity (Silver Spring); 2015 Oct; 23(10):2075-82. PubMed ID: 26331843
[TBL] [Abstract][Full Text] [Related]
25. Activation of the GLP-1 receptors in the nucleus of the solitary tract reduces food reward behavior and targets the mesolimbic system.
Richard JE; Anderberg RH; Göteson A; Gribble FM; Reimann F; Skibicka KP
PLoS One; 2015; 10(3):e0119034. PubMed ID: 25793511
[TBL] [Abstract][Full Text] [Related]
26. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
Secher A; Jelsing J; Baquero AF; Hecksher-Sørensen J; Cowley MA; Dalbøge LS; Hansen G; Grove KL; Pyke C; Raun K; Schäffer L; Tang-Christensen M; Verma S; Witgen BM; Vrang N; Bjerre Knudsen L
J Clin Invest; 2014 Oct; 124(10):4473-88. PubMed ID: 25202980
[TBL] [Abstract][Full Text] [Related]
27. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.
Farr OM; Sofopoulos M; Tsoukas MA; Dincer F; Thakkar B; Sahin-Efe A; Filippaios A; Bowers J; Srnka A; Gavrieli A; Ko BJ; Liakou C; Kanyuch N; Tseleni-Balafouta S; Mantzoros CS
Diabetologia; 2016 May; 59(5):954-65. PubMed ID: 26831302
[TBL] [Abstract][Full Text] [Related]
28. Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes.
ten Kulve JS; Veltman DJ; van Bloemendaal L; Barkhof F; Deacon CF; Holst JJ; Konrad RJ; Sloan JH; Drent ML; Diamant M; IJzerman RG
Diabetologia; 2015 Dec; 58(12):2688-98. PubMed ID: 26385462
[TBL] [Abstract][Full Text] [Related]
29. Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated With Glucose Homeostasis and Reward System.
Daniele G; Iozzo P; Molina-Carrion M; Lancaster J; Ciociaro D; Cersosimo E; Tripathy D; Triplitt C; Fox P; Musi N; DeFronzo R; Gastaldelli A
Diabetes; 2015 Oct; 64(10):3406-12. PubMed ID: 26116695
[TBL] [Abstract][Full Text] [Related]
30. Wired for obesity?
Selvarajah D; Choudhary P; Farooqi IS
Diabetes; 2014 Dec; 63(12):4016-7. PubMed ID: 25414020
[No Abstract] [Full Text] [Related]
31. GLP-1 receptor agonists: a review of head-to-head clinical studies.
Trujillo JM; Nuffer W; Ellis SL
Ther Adv Endocrinol Metab; 2015 Feb; 6(1):19-28. PubMed ID: 25678953
[TBL] [Abstract][Full Text] [Related]
32. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.
Finan B; Yang B; Ottaway N; Smiley DL; Ma T; Clemmensen C; Chabenne J; Zhang L; Habegger KM; Fischer K; Campbell JE; Sandoval D; Seeley RJ; Bleicher K; Uhles S; Riboulet W; Funk J; Hertel C; Belli S; Sebokova E; Conde-Knape K; Konkar A; Drucker DJ; Gelfanov V; Pfluger PT; Müller TD; Perez-Tilve D; DiMarchi RD; Tschöp MH
Nat Med; 2015 Jan; 21(1):27-36. PubMed ID: 25485909
[TBL] [Abstract][Full Text] [Related]
33. Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight.
Baggio LL; Drucker DJ
J Clin Invest; 2014 Oct; 124(10):4223-6. PubMed ID: 25202976
[TBL] [Abstract][Full Text] [Related]
34. Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes.
Ten Kulve JS; Veltman DJ; van Bloemendaal L; Barkhof F; Drent ML; Diamant M; IJzerman RG
Diabetes Care; 2016 Feb; 39(2):214-21. PubMed ID: 26283736
[TBL] [Abstract][Full Text] [Related]
35. Endogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumption.
Ten Kulve JS; Veltman DJ; van Bloemendaal L; Groot PF; Ruhé HG; Barkhof F; Diamant M; Ijzerman RG
J Endocrinol; 2016 Apr; 229(1):1-12. PubMed ID: 26769912
[TBL] [Abstract][Full Text] [Related]
36. Link Between Increased Satiety Gut Hormones and Reduced Food Reward After Gastric Bypass Surgery for Obesity.
Goldstone AP; Miras AD; Scholtz S; Jackson S; Neff KJ; Pénicaud L; Geoghegan J; Chhina N; Durighel G; Bell JD; Meillon S; le Roux CW
J Clin Endocrinol Metab; 2016 Feb; 101(2):599-609. PubMed ID: 26580235
[TBL] [Abstract][Full Text] [Related]
37. Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis.
Sun F; Chai S; Li L; Yu K; Yang Z; Wu S; Zhang Y; Ji L; Zhan S
J Diabetes Res; 2015; 2015():157201. PubMed ID: 25688373
[TBL] [Abstract][Full Text] [Related]
38. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat.
Larsen PJ; Tang-Christensen M; Jessop DS
Endocrinology; 1997 Oct; 138(10):4445-55. PubMed ID: 9322962
[TBL] [Abstract][Full Text] [Related]
39. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats.
Tang-Christensen M; Larsen PJ; Göke R; Fink-Jensen A; Jessop DS; Møller M; Sheikh SP
Am J Physiol; 1996 Oct; 271(4 Pt 2):R848-56. PubMed ID: 8897973
[TBL] [Abstract][Full Text] [Related]
40. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Pi-Sunyer X; Astrup A; Fujioka K; Greenway F; Halpern A; Krempf M; Lau DC; le Roux CW; Violante Ortiz R; Jensen CB; Wilding JP;
N Engl J Med; 2015 Jul; 373(1):11-22. PubMed ID: 26132939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
